Contents
Fluconazole Kabi is an antifungal medicine from the group of triazole derivatives for systemic use. The preparation can be used both in children and adolescents as well as in adults. It is recommended in the treatment of meningitis, infections of the mucous membranes (e.g. oral cavity) or as prevention of their recurrence. The active substance of this preparation is fluconazole. It is presented as a prescription infusion solution.
Fluconazole Kabi, Producent: Fresenius Kabi
| form, dose, packaging | availability category | the active substance |
| packaging: solution for infusion, 2 mg / ml, 50, 100 or 200 ml | prescription drug | fluconazole |
Indications for the use of Fluconazole Kabi
Adults.
- Treatment of: cryptococcal meningitis, coccidioidomycosis, invasive candidiasis, mucosal yeast infections (including infections of the throat, esophagus, urinary yeast, and chronic mucocutaneous infections), chronic oral candidiasis (stomatitis) when dental hygiene is insufficient.
- Prevention: recurrence of meningitis in patients at high risk blood cancer patients receiving chemotherapy or haematopoietic stem cell transplant patients.
Children and youth.
- Treatment of: yeast infections of the mucous membranes (mouth, throat and esophagus), invasive candidiasis and cryptococcal meningitis.
- Prophylaxis of yeast infections in immunocompromised patients.
The preparation can be used as a conservative therapy to prevent recurrence of cryptococcal meningitis in children at high risk of recurrence. Fluconazole Kabi should not be used to treat tinea pedis.
Contraindications to the use of Fluconazole Kabi
- Hypersensitivity to any component of the preparation or other azole derivatives,
- parallel treatment with cisapride, astemizole, pimozide, erythromycin or quinidine.
- Do not use terfenadine in patients receiving multiple doses of fluconazole 400 mg / day / day and above.
Fluconazole Kabi – dosage
Oral, pharyngeal and esophageal candidiasis in adults and children.
Adults.
- 200-400 mg on day 1, then 100-200 mg / day for 7-21 days for oropharyngeal candidiasis, 14-30 days for oesophageal candidiasis.
Infants and children up to 11 years of age on the 1st day.
- 6 mg / kg body weight / day, then 3 mg / kg body weight / day.
The presence of yeasts in the urine.
Adults.
- 200-400 mg / day for 7-21 days.
Chronic atrophic oral candidiasis if oral hygiene is inadequate.
Adults.
- 50 mg once / day for 1 days, additionally disinfecting dentures.
Invasive candidiasis in adults and children.
Adults.
- 800 mg on day 1, then 400 mg / day. Treatment usually lasts 2 weeks after the first negative blood culture result and symptoms have disappeared.
Babies and children up to 11 years of age
- 6-12 mg / kg body weight / day.
Chronic candidiasis of the skin and mucous membranes.
adults.
- 50-100 mg / day, for up to 28 days.
Cryptococcal meningitis in adults and children.
- 400 mg on day 1, then 200-400 mg once / day, usually for 1-6 weeks. In life-threatening infections, the dose may be increased to 8 mg / day.
- Infants and children up to 11 years of age 6-12 mg / kg body weight / day. In the prevention of relapses in patients at increased risk of relapse after full initial treatment, 200 mg once a day can be administered for a long time (1 mg / kg body weight / day in infants and children up to 11 years of age).
Coccidioidomycosis.
Adults.
- 200-400 mg / day, sometimes 800 mg / day, usually for 11-24 months
For the prevention of recurrence of oral and esophageal candidiasis in HIV-infected people (who are at increased risk of relapse).
Adults.
- 100-200 mg / day or 200 mg three times / week, for an unlimited period.
Prevention of fungal infections in immunocompromised patients with prolonged neutropenia (e.g. in patients with blood cancers receiving chemotherapy or bone marrow transplantation) in adults and children.
Adults.
200–400 mg / day several days before expected neutropenia. Continue treatment for up to 7 days after elevation of neutrophil counts> 1000 / mm3.
Babies and children up to 11 years of age
- 3-12 mg / kg body weight / day.
Serve by infusion iv at rate = <10 ml / min. The maximum dose in children and adolescents is 400 mg / day. In adolescents over 12 years of age, the dosage depends on body weight and maturity. For newborns, use the same doses as for infants and children, but for newborns 1-14. on the day, administer every 72 h (max. 12 mg / kg body weight / 72 h), and in newborns on 15–27. every 48 h (max. 12 mg / kg body weight / 48 h). In renal insufficiency (creatinine clearance = <50 ml / min), the usual dose should be administered on day 1, followed by half the usual dose. For patients undergoing hemodialysis, administer the usual dose after each treatment. In people with impaired liver function, the drug should be used with caution.
Fluconazole Kabi – side effects
Fluconazole Kabi may lead to the following side effects: headache, abdominal pain, vomiting, diarrhea, nausea, increased levels of: alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood alkaline phosphatase, rash.
Uncommon may occur: asthenia, change in appetite, insomnia, somnolence, convulsions, paraesthesia, dizziness, taste change, peripheral dizziness, constipation, dyspepsia, flatulence, dry mouth, cholestasis, jaundice, increased bilirubin, drug rash , hives, itching, increased sweating, muscle pain, fatigue, malaise, asthenia, fever.